Proposed model for the protective mechanism of CPE against CKD-induced HAS

The proposed model for the protective mechanism of CPE against CKD-induced HAS. Left: 5/6 NFx induces RAAS overactivation, leading to an increase in Ang II. This results in the upregulation of AT1R and the downregulation of AT2R and Mas1. These alterations establish a vasopressive state, reducing the GFR and allowing for the accumulation of uremic compounds. The sustained production of ROS, LP, and PC surpasses endogenous antioxidant systems, causing oxidative stress-mediated cellular damage and inflammation in the endothelium and smooth vascular muscle of the arteriole. This inflammatory environment triggers the expression of iNOS and the further oxidation of NO· to ONOO−, contributing to nitrative stress. Simultaneously, cellular damage leads to depletion in the glomeruli filtering barrier by diminishing nephrin and podocin, allowing for the occurrence of proteinuria. The persistent overactivation of RAAS increases the peripheral swiftness of arteries, culminating in endothelial dysfunction and the establishment of SAH. This perpetuates the decline in the GFR and the progression of CKD. Upon oral-gavage administration, CPE undergoes digestion, releasing chromo-peptides and PEB. These components mitigate ROS-mediated cellular damage through scavenging. Additionally, CPE prevents dysregulation in vasomodulation by normalizing the expression of AT1R, AT2R, and the Mas1/Akt1/eNOS pathway. Through these mechanisms, CPE maintains kidney function and prevents the establishment of SAH. CKD: Chronic kidney disease; BUN: Blood ureic nitrogen; GFR: Glomerular filtration rate; RAAS: Renin angiotensin aldosterone system; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; MAP: Mean arterial pressure; ROS: Reactive oxygen species; LP: Lipid peroxidation; PC: Protein carbonylation; CPE: C-phycoerythrin; PEB: Phycoerythrobilin. Dash line represents reduced pathway; bold line represents increased pathway. Created with Biorender.com
Proposed model for the protective mechanism of CPE against CKD-induced HAS

Publication

C-Phycoerythrin Prevents Chronic Kidney Disease-Induced Systemic Arterial Hypertension, Avoiding Oxidative Stress and Vascular Dysfunction in Remanent Functional Kidney (2024) Oscar Iván Florencio-Santiago, et al. Mar Drugs. 2024 Aug;22(8). Figure: F7.

Gene mentions


Organism Group Word Match Source NCBI Symbol NCBI ID
Homo sapiens Primates CPE CPE ncbigene_symbol CPE 1363
Homo sapiens Primates ACE2 ACE2 ncbigene_symbol ACE2 59272
Homo sapiens Primates AngII ANG2 ncbigene_synonym ANGPT2 285
Homo sapiens Primates AngII ANG2 ncbigene_synonym VPS51 738
Homo sapiens Primates Mas MAS ncbigene_synonym MAS1 4142
Homo sapiens Primates AKT AKT ncbigene_synonym AKT1 207
Homo sapiens Primates AKT AKT famplex_relations AKT2 208
Homo sapiens Primates AKT AKT famplex_relations AKT3 10000
Homo sapiens Primates eNOS ENOS ncbigene_synonym NOS3 4846
Homo sapiens Primates eNOS ENOS ncbigene_synonym ENO4 387712
Homo sapiens Primates Nephrin NEPHRIN ncbigene_synonym NPHS1 4868
Homo sapiens Primates AT1R AT1R ncbigene_synonym AGTR1 185
Homo sapiens Primates Mas1 MAS1 ncbigene_synonym PMPCB 9512
Homo sapiens Primates L-Arg LARG ncbigene_synonym ARHGEF12 23365
Homo sapiens Primates +GFR GFR ncbigene_synonym RAPGEF5 9771
Homo sapiens Primates SBP SBP ncbigene_synonym SHBG 6462
Homo sapiens Primates SBP SBP ncbigene_synonym CCHCR1 54535
Homo sapiens Primates DBP DBP ncbigene_symbol DBP 1628
Homo sapiens Primates DBP DBP ncbigene_synonym GC 2638
Homo sapiens Primates DBP DBP ncbigene_synonym HSD17B4 3295
Homo sapiens Primates MAP MAP ncbigene_synonym SGSM3 27352
Homo sapiens Primates TMAP TMAP ncbigene_synonym CKAP2 26586
Homo sapiens Primates SAH SAH ncbigene_synonym ACSM3 6296
Homo sapiens Primates .PC PC ncbigene_symbol PC 5091
Homo sapiens Primates INOS INOS ncbigene_synonym NOS2 4843
Homo sapiens Primates INOS INOS ncbigene_synonym ISYNA1 51477

Chemical mentions

Word Match MeSH Name ChEBI
Angiotensinogen Angiotensinogen chebi:2720
Ang II ang II chebi:48432
Angiotensinogen Angiotensinogen chebi:2720
Mas MAs chebi:25427
mage MAGE chebi:75883
GSSG GSSG (2S,2'S)-5,5'-[disulfanediylbis({(2R)-3-[(carboxymethyl)amino]-3-oxopropane-1,2-diyl}imino)]bis(2-amino-5-oxopentanoic acid) chebi:17858
GSH GSH L-gamma-glutamyl-L-cysteinylglycine chebi:16856
L-Arg L-Arg L-arginine chebi:16467
ROS ROS chebi:26523
ROS ROS chebi:26523
Creatinine creatinine creatinine chebi:16737
DBP DBP dibutyl benzene-1,2-dicarboxylate chebi:34687
SAH SAH S-(5'-deoxyadenosin-5'-yl)-L-homocysteine chebi:16680
ROS ROS chebi:26523
MAP MAP (6alpha)-6-methyl-3,20-dioxopregn-4-en-17-yl acetate chebi:6716
GSH GSH L-gamma-glutamyl-L-cysteinylglycine chebi:16856
Ang II ang II chebi:48432
ROS ROS chebi:26523
DBP DBP dibutyl benzene-1,2-dicarboxylate chebi:34687
SAH SAH S-(5'-deoxyadenosin-5'-yl)-L-homocysteine chebi:16680
MAP MAP (6alpha)-6-methyl-3,20-dioxopregn-4-en-17-yl acetate chebi:6716
Creatinine creatinine creatinine chebi:16737

Disease mentions

Word Match MeSH Name DOID
Proteinuria proteinuria proteinuria DOID:576